Hengrui Pharmaceutical has ushered in good news in the field of diabetes drugs!

【Pharmaceutical Network Company News】Diabetes is a clinical metabolic disease characterized by hyperglycemia, and its treatment drugs can be divided into two categories: non-insulin hypoglycemic drugs and insulin hypoglycemic drugs, subdivided into ten categories
, such as biguanides, insulin and its analogues, GLP-1 receptor agonists, sulfonylureas, glinides, GKA drugs, etc.
With the increase in the number of patients and other factors, in recent years, the global diabetes drug market is showing a year-by-year growth trend, which has also attracted more enterprises
.
At present, the market competition for insulin and non-insulin hypoglycemic drugs is becoming increasingly fierce
.
According to the data, a total of 3142 drug indications worldwide have included diabetes, of which 1461 are under development
.
Among the drugs under development, more have been developed for the indication of type 2 diabetes
.
In China, the indications of 561 drug candidates have included diabetes, and among local companies, Hengrui Pharmaceutical, Tonghua Dongbao, China Biopharmaceutical, and Huadong Medicine have more drugs under development in this field
.
Among them, taking Hengrui Pharmaceutical as an example, it has made an extensive R&D pipeline layout
in the field of diabetes in recent years.
At the end of 2021, Hengrui Pharmaceutical's first Class 1 innovative drug in the field of diabetes was approved for marketing, which took 10 years of research and development and belongs to the innovative SGLT2 inhibitor
.
Hengrui Pharmaceutical is also developing combination preparations of hengliflozin with metformin and DPP-4 inhibitors
.
In terms of GLP-1/GIP dual-target agonists, which are now popular in the field of glucose reduction, Hengrui Pharmaceutical has also made a layout
.
It is worth mentioning that on November 28, Hengrui Pharmaceutical announced that Shandong Shengdi Pharmaceutical Co.
, Ltd.
, a subsidiary of the company, recently received the approval of the State Food and Drug Administration to issue the "Drug Clinical Trial Approval Notice" for HR20031 tablets, and will carry out clinical trials
in the near future.
HR20031 tablets are fixed-dose tripartite preparations of proline hengliflozin, repagliptin phosphate and metformin hydrochloride (sustained-release) developed by the company, which are intended to be orally administered once daily for the treatment of type 2 diabetes mellitus
in which blood sugar is still poorly controlled after metformin treatment.
HR20031 tablets are expected to achieve better hypoglycemic effect
through three different mechanisms of action.
Up to now, HR20031 related projects have invested a total of about 9.
13 million yuan
in R&D expenses.
After inquiry, there are two similar SGLT2 inhibitors, DPPIV inhibitors and metformin sustained-release tripartite preparations that have been marketed abroad: TrijardyXR (empagliflozin/lintagliptin/metformin sustained-release tablets) of the Boehringer-Eli Lilly Diabetes Alliance and QternmetXR (dapagliflozin/saxagliptin/metformin sustained-release tablets) of AstraZeneca, and no relevant sales data have been queried at present, and no similar drugs have been approved for marketing
in China 。 Industry analysts believe that under the normalization of volume procurement and the consistency evaluation policy of generic drugs, the competition in the domestic diabetes generic drug market is gradually entering the white heat, and at the same time, it is also forcing domestic companies to accelerate from generic drugs to fast-follow and first-in-class
.
The research and development of pharmaceutical companies has accelerated, and many pharmaceutical companies have gathered hot targets and competed for involvement
.
In this context, it is expected that in addition to Hengrui Pharmaceutical, more and more new diabetes drugs from pharmaceutical companies will enter the clinical stage and submit marketing applications
in China.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.